Published in J Hepatocell Carcinoma on April 24, 2015
Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Liver regeneration. Science (1997) 12.80
Molecular cloning and expression of human hepatocyte growth factor. Nature (1989) 6.91
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (1987) 6.26
Scatter factor/hepatocyte growth factor is essential for liver development. Nature (1995) 5.91
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature (1995) 4.68
Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell (2011) 4.54
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 4.41
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun (1984) 3.70
Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer (2006) 3.45
CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev (2002) 3.07
Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A (2004) 2.77
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol (2001) 2.72
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell (2001) 2.62
Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res (1989) 2.59
Lack of Fas antagonism by Met in human fatty liver disease. Nat Med (2007) 2.48
A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28
MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology (2014) 1.97
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest (2002) 1.93
Invasive growth: from development to metastasis. J Clin Invest (2002) 1.91
A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell (2002) 1.82
c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol (2011) 1.81
Cancer therapy: can the challenge be MET? Trends Mol Med (2005) 1.81
MicroRNAs impair MET-mediated invasive growth. Cancer Res (2008) 1.81
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res (1999) 1.74
Partial characterization of a hepatocyte growth factor from rat platelets. J Cell Physiol (1984) 1.56
Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev (2008) 1.52
Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology (1997) 1.50
Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res (2007) 1.43
The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A (1991) 1.40
Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res (2013) 1.39
Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun (1998) 1.37
Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ (1996) 1.36
Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest (1996) 1.27
Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem (1994) 1.26
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology (2013) 1.26
Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem (1993) 1.21
Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology (1994) 1.21
Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog (2003) 1.19
Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res (2000) 1.17
Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol (2005) 1.17
Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg (2007) 1.16
Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther (2005) 1.15
Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene (1997) 1.12
u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer (2000) 1.12
Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res (1995) 1.10
Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene (1998) 1.09
Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol (2012) 1.08
Ets up-regulates MET transcription. Oncogene (1996) 1.06
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer (2013) 1.05
HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. J Clin Invest (2013) 1.04
Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res (2014) 1.00
Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet (2001) 0.99
Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem (2004) 0.98
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther (2014) 0.97
Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein. Biochem Biophys Res Commun (1991) 0.96
Hepatocyte growth factor receptor in acute tubular necrosis. J Am Soc Nephrol (2001) 0.96
c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Gastroenterology (2009) 0.94
Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways. Biochim Biophys Acta (2012) 0.92
Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. Hepatology (1996) 0.91
HGF-mediated apoptosis via p53/bax-independent pathway activating JNK1. Carcinogenesis (1999) 0.90
Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J Surg Res (2009) 0.90
MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met. Biochem Biophys Res Commun (2014) 0.90
Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a transcription factor Ets-1. Hepatol Res (2003) 0.89
Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene (2003) 0.89
A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res (2013) 0.88
Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met. Int J Cancer (2009) 0.84
Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation. Oncogene (2002) 0.82
Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. J Hepatol (2014) 0.82
Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamine. Carcinogenesis (1995) 0.81
Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. PLoS One (2014) 0.78